|
| Press Releases |
|
 |
|
| Friday, March 27, 2026 |
|
|
Hua Medicine Announces 2025 Annual Results |
| Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552) announces the audited consolidated results of the Company and its subsidiaries for the year ended December 31, 2025 (the 'Reporting Period'). more info >> |
|
|
華領醫藥公佈2025年全年業績 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年12月31日止年度（「報告期」）經審核的綜合業績。 more info >> |
|
|
华领医药公布2025年全年业绩 |
| 华领医药（"公司"，香港联交所股份代号：2552）宣布公司及其附属公司截至2025年12月31日止年度（"报告期"）经审核的综合业绩 more info >> |
|
| Tuesday, March 3, 2026 |
|
|
華領醫藥宣佈多格列艾汀在中國香港獲批上市 |
| 華領醫藥（「公司」，香港聯交所股份代號：2552）今日宣佈，其全球首創新藥葡萄糖激酶激活劑（GKA）多格列艾汀（dorzagliatin）（商品名：MYHOMSIS(R)，華領片(R)）已獲中國香港特別行政區政府衛生署藥物辦公室批准上市，用於治療成人2型糖尿病。 more info >> |
|
|
华领医药宣布多格列艾汀在中国香港获批上市 |
| 华领医药（"公司"，香港联交所股份代号：2552）今日宣布，其全球首创新药葡萄糖激酶激活剂（GKA）多格列艾汀（dorzagliatin）（商品名：MYHOMSIS(R)，華領片(R)）已获中国香港特别行政区政府卫生署药物办公室批准上市，用于治疗成人2型糖尿病。 more info >> |
|
|
Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China |
| Hua Medicine ("the Company", Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS(R)) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults. more info >> |
|
| Monday, September 29, 2025 |
|
|
Hua Medicine Announces the Pharmaceutical Service of Hong Kong Department of Health of China has Officially Accepted the Application for Marketing Authorization of the New Drug Dorzagliatin |
| Hua Medicine (HKEX: 2552) announced that the Department of Health of the Hong Kong Special Administrative Region of China accepted a New Drug Application (NDA) for dorzagliatin, the world's first glucokinase activator (GKA) approved for the treatment of Type 2 diabetes (T2D). more info >> |
|
|
华领医药宣布中国香港卫生署药物办公室正式受理多格列艾汀新药上市许可申请 |
| 华领医药（"公司"，香港联交所股份代号：2552）宣布，中国香港特别行政区卫生署已正式受理多格列艾汀（dorzagliatin）的新药上市许可申请（NDA）。多格列艾汀是世界上第一个获批准用于治疗2型糖尿病（T2D）的葡萄糖激酶激活剂（GKA）。 more info >> |
|
|
華領醫藥宣佈中國香港衛生署藥物辦公室正式受理多格列艾汀新藥上市許可申請 |
| 華領醫藥（"公司"，香港聯交所股份代號：2552）宣佈，中國香港特別行政區衛生署已正式受理多格列艾汀（dorzagliatin）的新藥上市許可申請（NDA）。多格列艾汀是世界上第一個獲批准用于治療2型糖尿病（T2D）的葡萄糖激酶激活劑（GKA）。 more info >> |
|
| Thursday, August 28, 2025 |
|
|
Hua Medicine Announces 2025 Interim Results |
| Hua Medicine (the 'Company', HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the 'Reporting Period'), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing'(dorzagliatin tablets), accelerated. The Company's independent operational capabilities improved significantly. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
OSL Lists State-Supervised Gold-Backed Stablecoin USDKG as Platform Expands Asia's Digital Asset Ecosystem
May 22, 2026 23:30: JST
|
|
|
OSL Lists State-Supervised Gold-Backed Stablecoin USDKG as Platform Expands Asia's Digital Asset Ecosystem
May 22, 2026 22:30 HKT/SGT
|
|
|
Six Factors to Consider When Opting for a Credit Line in Singapore
May 22, 2026 19:05 HKT/SGT
|
|
|
Patents Build Solid Barriers, Technologies Achieve All-Round Breakthroughs, New Vision Leads the New Track of AR Interaction
May 22, 2026 17:46 HKT/SGT
|
|
|
天辰生物通過聆訊：深耕過敏與自身免疫領域 臨床療效全面領先
May 22, 2026 16:32 HKT/SGT
|
|
|
天辰生物通过聆讯：深耕过敏与自身免疫领域 临床疗效全面领先
May 22, 2026 16:32 HKT/SGT
|
|
|
Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit
May 22, 2026 11:05: JST
|
|
|
雲頂新耀獲主要股東康橋資本增持 全球化佈局有望持續受益
May 22, 2026 10:59 HKT/SGT
|
|
|
GTJAI Won Two Awards at HR Asia 2026
May 22, 2026 10:49 HKT/SGT
|
|
|
國泰君安國際斬獲HR Asia 2026年度兩項大獎
May 22, 2026 10:49 HKT/SGT
|
|
|
国泰君安国际斩获HR Asia 2026年度两项大奖
May 22, 2026 10:49 HKT/SGT
|
|
|
Everest Medicines Receives Shareholding Increase from Substantial Shareholder CBC Group, Global Expansion Expected to Benefit
May 22, 2026 10:05 HKT/SGT
|
|
|
云顶新耀获主要股东康桥资本增持 全球化布局有望持续受益
May 22, 2026 10:05 HKT/SGT
|
|
|
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 22, 2026 0:23 JST
|
|
|
Honda to Begin Sales of Super-ONE Compact EV
May 22, 2026 0:16 JST
|
|
|
|
|
More News >> |
|
|
|
|
|
